Product Description
Mechanisms of Action: CYP3A4 Inhibitor,TK Inhibitor,EGFR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer
Phase 2: Non-Small-Cell Lung Cancer|Small Cell Lung Cancer
Phase 1: Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SOLAR | P3 |
Completed |
Non-Small-Cell Lung Cancer |
2017-12-21 |
22% |
| SOLAR | P3 |
Terminated |
Non-Small-Cell Lung Cancer |
2017-12-21 |
22% |
| 8273-CL-0102 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2017-07-28 |
12% |
| 8273-CL-0202 | P2 |
Terminated |
Small Cell Lung Cancer|Non-Small-Cell Lung Cancer |
2017-06-09 |
|
| 8273-CL-0112 | P1 |
Terminated |
Non-Small-Cell Lung Cancer |
2017-05-12 |
|
| 8273-CL-0201 | P2 |
Withdrawn |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer |
2017-02-28 |
|
| 8273-CL-0104 | P1 |
Withdrawn |
Oncology Solid Tumor Unspecified |
2016-11-15 |
|
| 8273-CL-0101 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2016-01-15 |